July 8, 2012

Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

.   .   

Tofacitinib is the first in a new class of immunosuppressive agents that inhibit janus kinase, an important transcription factor. This randomized-controlled trial compared tofacitinib to cyclosporine in renal transplant patients. Tofacitinib showed lower rates of acute rejection and chronic changes on biopsy, with better renal function compared to a cyclosporine-based regimen. On the other hand, infections, hematologic side effects and PTLD were all more common. Whether adjustments in the dose of tofacitinib will allow for good results with fewer side effects remains to be seen.

Related Articles:

Renal Transplantation

Comments are closed.